Document 0809
 DOCN  M9590809
 TI    Frequent use of menfegol spermicidal vaginal foaming tablets associated
       with a high incidence of genital lesions.
 DT    9509
 AU    Goeman J; Ndoye I; Sakho LM; Mboup S; Piot P; Karam M; Belsey E; Lange
       JM; Laga M; Perriens JH; Department of Infection and Immunity, Institute
       of Tropical; Medicine, Antwerp, Belgium.
 SO    J Infect Dis. 1995 Jun;171(6):1611-4. Unique Identifier : AIDSLINE
       MED/95287059
 AB    Menfegol is a spermicide with in vitro activity against human
       immunodeficiency virus (HIV). A randomized placebo-controlled safety
       study covered the use of menfegol foaming tablets for 14 days at
       increasing frequencies of insertion by 125 prostitutes in Dakar,
       Senegal. The frequencies of colposcopically diagnosed genital lesions
       were 5.0%, 11.8%, 27.8%, 49.7%, and 29.4% among menfegol recipients when
       tablets were used once every other day or 1, 2, 4, or 8 times a day,
       respectively (P < .05). Among placebo recipients, frequencies were 11.1%
       and 23.5% when tablets were used < 8 times daily and 8 times daily,
       respectively. There was no association between subjective genital
       symptoms and the incidence of colposcopically detected lesions. The high
       incidence of genital lesions when menfegol foaming tablets were used
       more than once daily suggests that their frequent use should not be
       recommended to prevent HIV transmission. In use at low frequency, the
       tablets' toxicity might be balanced by anti-HIV properties. Safety
       studies on vaginal microbicides should use objective methods, such as
       colposcopy, to assess the incidence of lesions.
 DE    Adult  Cervix Diseases/*CHEMICALLY INDUCED  Contraceptive Agents,
       Female/*ADVERSE EFFECTS  Double-Blind Method  Female  Human  Mucous
       Membrane/DRUG EFFECTS  Polyethylene Glycols/*ADVERSE EFFECTS
       Prostitution  Research Design  Support, Non-U.S. Gov't  Vaginal
       Diseases/*CHEMICALLY INDUCED  CLINICAL TRIAL  JOURNAL ARTICLE
       RANDOMIZED CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).